Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Cemdisiran by Alnylam Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...